Stock Groups

Biogen’s research chief Alfred Sandrock to retire -Breaking

[ad_1]

2/2
© Reuters. FILE PHOTO – A sign marks the Biogen facility at Cambridge, Massachusetts. U.S.A., January 26, 2017. REUTERS/Brian Snyder

2/2

(Reuters: Biogen Inc. (NASDAQ:) on Monday announced that Alfred Sandrock, the research chief at Biogen, has resigned. Sandrock was instrumental in developing Aduhelm for Alzheimer’s Disease and is retiring after a successful 23-year career.

The company said Sandrock will retire by the end of this year, and Priya Singhal will lead the research & development unit on an interim basis until a permanent successor is identified.

Biogen’s controversial drug Aduhelm was portrayed by Sandrock. It was approved in June by the U.S. Food and Drug Administration for its ability remove sticky deposits from another protein, amyloid beta – a potential contributor to Alzheimer’s.

Experts have raised questions about the FDA’s rationale in approving this drug without further proof.

Sandrock, who graduated from Stanford University, joined the drugmaker as a chief medical officer in 1998. Before joining Biogen’s executive committee, he had been the chief medical officers for Biogen for around eight years.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses as a result.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]